|
|---|
|
Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2009 Results on February 11, 2010
Thursday, Jan 28, 2010
|
|
| |
CHESHIRE, Conn., Jan 28, 2010 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the
Company will report its financial results for the fourth quarter and
year ended December 31, 2009 on Thursday, February 11, 2010 before the
financial markets open. Following the release of the financial res...
|
|
|
Alexion to Present at the 28th Annual JP Morgan Healthcare Conference
Wednesday, Jan 6, 2010
|
|
| |
CHESHIRE, Conn., Jan 06, 2010 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at the 28th Annual JP Morgan Healthcare Conference in San
Francisco at 3:00 p.m. local time (6:00 p.m. Eastern) on Wednesday,
...
|
|
|
Soliris(R) Reduced Hemolysis, Lowered Thrombosis Rate and Improved Quality of Life in Patients with PNH Who Had Previously Never Been Transfused
Monday, Dec 7, 2009
|
|
| |
CHESHIRE, Conn., Dec 07, 2009 (BUSINESS WIRE) -- New data presented today demonstrate the severe clinical burden of paroxysmal
nocturnal hemoglobinuria (PNH) and the clinical benefits of Soliris(R)
(eculizumab) in 44 patients with no history of prior blood
transfusions. Prior to Soliris treatment, these never-transfused
...
|
|
|
Soliris® Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting
Monday, Dec 7, 2009
|
|
| |
CHESHIRE, Conn., Dec 07, 2009 (BUSINESS WIRE) -- Soliris®
(eculizumab), a
first-in-class terminal complement inhibitor developed by Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN), reversed
thrombocytopenia (abnormally low platelet count) in a significant
proportion of patients ...
|
|
|
Soliris(R) Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders
Sunday, Dec 6, 2009
|
|
| |
CHESHIRE, Conn., Dec 06, 2009 (BUSINESS WIRE) -- Soliris(R)
(eculizumab), a first-in-class terminal complement inhibitor
developed by Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced hemolysis (destruction
of red blood cells) and transfusion requirements, and improved measures
of fatigue, when added to o...
|
|
|
Researchers Report Clinical Association Between Type II PNH Cells and Thrombocytopenia
Sunday, Dec 6, 2009
|
|
| |
CHESHIRE, Conn., Dec 06, 2009 (BUSINESS WIRE) -- Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced presentation of
data showing that the presence of Type II paroxysmal
nocturnal hemoglobinuria (PNH) cells is correlated with
thrombocytopenia, potentially indicating that patients with Type II
cells e...
|
|
|
Long-Term Soliris(R) Treatment Resulted in Sustained Reduction in Hemolysis and Improved Kidney Function in Japanese Patients with PNH
Saturday, Dec 5, 2009
|
|
| |
CHESHIRE, Conn., Dec 05, 2009 (BUSINESS WIRE) -- Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced positive data
from the 26-week extension of the AEGIS study, an open-label
registration study examining Soliris(R)
(eculizumab) for the treatment of Japanese patients with paroxysmal
nocturnal hemoglo...
|
|
|
Alexion Reports Progress on Commissioning of Rhode Island Manufacturing Facility as Second Source of Supply
Wednesday, Dec 2, 2009
|
|
| |
CHESHIRE, Conn., Dec 02, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today provided updates on
the regulatory review and approval, or commissioning, of Alexion's Rhode
Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a
second source of supply for Soliris(R) (eculizumab). The
...
|
|
|
Alexion Appoints William R. Keller to its Board of Directors
Tuesday, Dec 1, 2009
|
|
| |
CHESHIRE, Conn., Dec 01, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Mr.
William R. Keller has been appointed a Director of Alexion, effective
immediately. With Mr. Keller's appointment, there are now eight members
of Alexion's Board of Directors.
About William KellerMr. Keller ...
|
|
|
Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Wednesday, Nov 11, 2009
|
|
| |
CHESHIRE, Conn., Nov 11, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at Lazard Capital Markets 6th Annual Healthcare
Conference in New York City at 10:00 a.m. ET on Wednesday, November 18,
...
|
|
|
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
Tuesday, Nov 10, 2009
|
|
| |
CHESHIRE, Conn., Nov 10, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that
researchers are scheduled to present data relating to Soliris(R)
(eculizumab) as a treatment for patients with paroxysmal nocturnal
hemoglobinuria (PNH) during the 51st Annual Meeting of the American
Soc...
|
|
|
Alexion to Present at Credit Suisse's 2009 Healthcare Conference
Thursday, Nov 5, 2009
|
|
| |
CHESHIRE, Conn., Nov 05, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at Credit Suisse's 2009 Healthcare Conference in Phoenix,
Arizona at 8:00 a.m., local time (10:00 a.m. ET) on Thursday, November...
|
|
|
Alexion to Present at the Oppenheimer 20th Annual Healthcare Conference
Wednesday, Oct 28, 2009
|
|
| |
CHESHIRE, Conn., Oct 28, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at the Oppenheimer 20th Annual Healthcare Conference
in New York City at 3:55 p.m. ET on Wednesday, November 4, 2009.
An audio ...
|
|
|
Alexion Reports Third Quarter 2009 Results
Thursday, Oct 22, 2009
|
|
| |
CHESHIRE, Conn., Oct 22, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company," NASDAQ: ALXN)
today announced financial results for the quarter ended September 30,
2009.
Third Quarter 2009 Financial Results:For the three months ended September 30, 2009, Alexion reported total
revenues of $102.6 m...
|
|
|
Alexion Pharmaceuticals to Report Third Quarter 2009 Results on October 22, 2009
Monday, Oct 12, 2009
|
|
| |
CHESHIRE, Conn., Oct 12, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the
Company will report its financial results for the third quarter ended
September 30, 2009 on Thursday, October 22, 2009 before the financial
markets open. Following the release of the financial results, Alex...
|
|
|
Alexion to Present at the UBS Global Life Sciences Conference
Wednesday, Sep 16, 2009
|
|
| |
CHESHIRE, Conn., Sep 16, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr.
Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will
present at the UBS Global Life Sciences Conference in New York City at
3:30 p.m. ET on Tuesday, September 22, 2009.
An audio webcast of...
|
|
|
Alexion to Present at Investor Conferences
Tuesday, Sep 8, 2009
|
|
| |
CHESHIRE, Conn., Sep 08, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that
management will present at two upcoming investor conferences:
Mr. Vikas Sinha, Chief Financial Officer of Alexion, will present at the
Thomas Weisel Partners Healthcare Conference 2009 in Boston on Friday,
Sept...
|
|
|
European Commission and U.S. FDA Grant Alexion's Soliris® (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
Thursday, Aug 6, 2009
|
|
| |
CHESHIRE, Conn., Aug 06, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R)
(eculizumab), its first-in-class complement inhibitor, has been granted
Orphan Medicinal Product Designation by the European Commission for the
treatment of patients with atypical Hemolytic Uremic Syn...
|
|
|
Alexion Reports Second Quarter 2009 Results
Thursday, Jul 23, 2009
|
|
| |
CHESHIRE, Conn., Jul 23, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial
results for the quarter ended June 30, 2009.
Second Quarter 2009 Financial Results:For the three months ended June 30, 2009, Alexion Pharmaceuticals, Inc.
("Alexion" or the "Company") reported total revenues of $9...
|
|
|
Alexion Pharmaceuticals to Report Second Quarter 2009 Results on July 23, 2009
Thursday, Jul 9, 2009
|
|
| |
CHESHIRE, Conn., Jul 09, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the
Company will report its financial results for the second quarter ended
June 30, 2009 on Thursday, July 23, 2009 before the financial markets
open. Following the release of the financial results, Alexion man...
|
|
|